Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2023

Open Access 01-12-2023 | Acquired Immune Deficiency Syndrome | Research

Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China

Authors: Susu Ke, Quan Fang, Jianguo Lan, Nini Qiao, Xinhong Zhang, Changping Xie, Yinguang Fan

Published in: BMC Public Health | Issue 1/2023

Login to get access

Abstract

Background

To compare the survival rates of four timing of treatment initiation for people living with HIV/AIDS provided in China in 2006, 2011, 2015, and 2018, and to investigate the factors impacting survival time.

Methods

A people living with HIV/AIDS retrospective cohort study was in Liuzhou City from April 2006 to December 2020. The information was obtained from the National Comprehensive AIDS Prevention and Control Information System. Life tables and the Kaplan–Meier method were used to calculate participant survival rates and time. The univariate and multivariate Cox regression models were used to investigate the factors related to survival.

Results

18,543 participants were included in this study. In four periods, the 1-year survival rates were 81%, 87%, 95%, and 95%. The 2-year survival rates were 76%, 85%, 93%, and 94%. The 3-year survival rates were 73%, 84%, 92%, and 94%. Results of multivariate Cox regression showed that sex, age of HIV diagnosis, ethnicity, household registration, occupation, marital status, the timing of treatment, education level, route of HIV transmission, whether receiving antiretroviral therapy (ART), and the count of CD4+T cells at baseline (count of CD4+T cells at HIV diagnosis) were factors that are significantly correlated with mortality caused by HIV infection.

Conclusions

With the Guidelines updated from 2006 to 2020, the 1-, 2-, and 3-year survival rates of people living with HIV/AIDS in four periods tended to increase. The timing of treatment initiation of the updated edition of the AIDS Diagnostic and Treatment Guidelines (Guidelines) significantly prolonged the survival time of people living with HIV/AIDS.
Appendix
Available only for authorised users
Literature
1.
Li Y, Zhang XW, Liao B, Liang J, He WJ, Liu J, Yang Y, Zhang YH, Ma T, Wang JY. Social support status and associated factors among people living with HIV/AIDS in Kunming city, China. BMC Public Health. 2021;21(1):1413.CrossRefPubMedPubMedCentral
2.
3.
Judd A, Chappell E, Turkova A, Le Coeur S, Noguera-Julian A, Goetghebuer T, Doerholt K, Galli L, Pajkrt D, Marquess L, et al. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: a cohort study. PLos Med. 2018;15(1): e1002491.CrossRefPubMedPubMedCentral
4.
Trickey A, May MT, Vehreschild JJ, Obel N, Gill MJ, Crane HM, Boesecke C, Patterson S, Grabar S, Cazanave C, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):E349–56.CrossRef
5.
Zhang HX, Han MJ, Zhou Y, Xiu XF, Xu F, Wang L. Interrupted time series analysis for influence on HIV related fatality of implementation of “Four Free Services One Care” policy in China. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020;41(3):406–11.PubMed
6.
Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M, Bonarek M, Monforte AD, Esteve A, Gill MJ, Harris R, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–9.CrossRef
7.
Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD. Investigators HIVOS: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138(8):620–6.CrossRefPubMed
8.
9.
Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, et al. Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society-USA Panel. JAMA-J Am Med Assoc. 2014;312(4):410–25.CrossRef
10.
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miro JM, Ferrer E, et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV. 2015;2(8):E335–43.CrossRefPubMed
11.
Wang AX, Wang FS, Wang QY, Jian W, Feng TJ, Lu HZ, Sun HQ, Sun YT, Ye HH, Li TS, et al. Guidelines for diagnosis and treatment of HIV/AIDS in China (2005). Chin Med J. 2006;119(19):1589–608.CrossRef
12.
Wang AX WF, Mao Q. Guidelines for diagnosis and treatment of AIDS. Proceedings of the Fifth National Conference on HIV/AIDS, Viral Hepatitis C and National Tropical Diseases of the Chinese Medical Association. 2011. p. 57–78.
13.
Sun J-J, Lu H-Z. Highlights of the third edition of Chinese guidelines for AIDS diagnosis and treatment(2015). Zhejiang da xue xue bao Yi xue ban = J Zhejiang Univ Med Sci. 2015;44(6):597–602.
14.
Aids, Hepatitis C Professional Group SoIDCMA, Chinese Center for Disease C, Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018). Zhonghua Nei Ke Za Zhi. 2018;57(12):867–84.
15.
16.
Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulle AM, Abebo TA, Abera SF, Aboyans V, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260–344.CrossRef
17.
18.
Zhang YJFX, Fan YG, et al. HIV transmission and related risk factors among serodiscordant couples in Liuzhou. China J Med Virol. 2015;87(4):553–6.CrossRefPubMed
19.
Lan GHSZ, Ge XM, et al. Review and prospect of comprehensive prevention, control and management of acquired immune deficiency syndrome in Guangxi. Chinese J New Clin Med. 2021;14(10):1674–3806.
20.
Wang LQQ, Ding ZHW, et al. Current case reporting of HIV/A IDS epidemic in China 2010. Chin J AIDS STD. 2011;17(3):275–8.
21.
Fu YS, Ashuro AA, Feng XX, Wang T, Zhang SC, Ye DQ, Fan YG. Willingness to use HIV pre-exposure prophylaxis and associated factors among men who have sex with men in Liuzhou, China. Aids Res Ther. 2021;18(1):46.CrossRefPubMedPubMedCentral
22.
Dong XY HA, Li ZHX, et al. Survival analysis among HIV-infected individual and AIDS patients in Baoshan, Yunnan, 1990–2020. J Trop Med. 2021;21(11):1075–80.
23.
Jiang XM WH. Analysis of survival time and factors influencing HIV/AIDS in Nanping City, 1998–2020. Strait J Prev Med. 2021;27(04):28–31.
24.
Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D’Arminio Monforte A, de Wolf F, Reiss P, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (London, England). 2002;360(9327):119–29.CrossRefPubMed
25.
Li M, Tang WM, Bu K, Mahapatra T, Zhang XY, Feng YB, Chen FF, Guo W, Wang LY, Ding ZW, et al. Mortality among people living with HIV and AIDS in China: implications for enhancing linkage. Sci Rep. 2016;6:28005.CrossRefPubMedPubMedCentral
26.
Carriquiry G, Fink V, Koethe JR, Giganti MJ, Jayathilake K, Blevins M, Cahn P, Grinsztejn B, Wolff M, Pape JW, et al. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean. J Int AIDS Soc. 2015;18:20016.CrossRefPubMedPubMedCentral
27.
Kim YC, Ahn JY, Kim HY, Song JY, Park DW, Kim MJ, Choi HJ, Kim SW, Kee MK, Han MG, et al. Survival trend of HIV/AIDS patients starting antiretroviral therapy in South Korea between 2001 and 2015. Yonsei Med J. 2020;61(8):705–11.CrossRefPubMedPubMedCentral
28.
29.
Cheng D, Fan W, Shan YF. The first detection results of CD4* T lymphocytes in newly confirmed HIV infected persons/AIDS patients in Xinxiang city from 2015 to 2020. J Trop Med. 2023;23(02):263–6.
30.
Crabtree-Ramirez BE, Caro-Vega Y, Belaunzaran-Zamudio PF, Shepherd BE, Rebeiro PF, Veloso V, Cortes CP, Padgett D, Gotuzzo E, Sierra-Madero J, et al. Temporal changes in ART initiation in adults with high CD4 counts in Latin America: a cohort study. J Int AIDS Soc. 2019;22(12):6.CrossRef
31.
Hoenigl M, Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ. Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. JAIDS. 2016;71(5):551–7.PubMed
32.
Liu DC, Jiang ZX, Xiu CZ, Li ZZ, Song Q, Wang ZH. Sexually transmitted infection prevalence and related risk factors among heterosexual male methamphetamine users in China. Int J STD AIDS. 2017;28(12):1208–14.CrossRefPubMed
33.
Robertson AM, Syvertsen JL, Ulibarri MD, Rangel MG, Martinez G, Strathdee SA. Prevalence and correlates of HIV and sexually transmitted infections among female sex workers and their non-commercial male partners in two Mexico-USA Border Cities. J Urban Health. 2014;91(4):752–67.CrossRefPubMedPubMedCentral
34.
Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpe JB, Minga A, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRefPubMed
35.
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ-Br Med J. 2011;343: d6016.CrossRef
36.
Lundgren D, Babiker AG, Gordin F, Emery S, Sharma S, Avihingsanon AC, Cooper DA, Fatkenheuer G, Llibre JM, Moli-Na JM, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRefPubMed
Metadata
Title
Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
Authors
Susu Ke
Quan Fang
Jianguo Lan
Nini Qiao
Xinhong Zhang
Changping Xie
Yinguang Fan
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2023
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-023-15662-3

Other articles of this Issue 1/2023

BMC Public Health 1/2023 Go to the issue

Research

Role of social determinants of health in differential respiratory exposure and health outcomes among children

Research

Sexual orientation knowledge and attitudes and its association with therapy satisfaction among lesbian, gay, and bisexual + Hispanic Puerto Ricans

Research

Association between biomarkers of redox status and cytokines with different patterns of habitual physical activity in eutrophic and overweight/obese preschoolers: multivariate analysis of a cross-sectional study

Research

Evaluating the impact of marketing interventions on sugar-free and sugar-sweetened soft drink sales and sugar purchases in a fast-food restaurant setting

Research

Adolescents’ experiences of a school-based health promotion intervention in socioeconomically advantaged and disadvantaged areas in Sweden: a qualitative process evaluation study

Research

Exposure to pesticides and the risk of hypothyroidism: a systematic review and meta-analysis